Celeris Therapeutics

📍 Menlo Park, United States🗓 Founded 2021👥 20 employees💰 Last funded Aug 2021
Pharmaceutical Manufacturing🌐 celeristx.com
Website LinkedIn
Celeris Therapeutics is going to solve the R&D shortcomings as the pioneer in AI-driven PIC (proximity-inducing compounds) design using an innovative closed-loop engine (Celeris One™ platform) to develop new chemical entities (NCEs) that degrade proteins by establishing proximity to endogenous cellular mechanisms. The solutions include machine learning-driven prediction of interactions, generative design, optimization of molecular properties, and automation of laboratory devices. CelerisTx's drug pipeline is focused on CNS and oncology, targeting unmet medical needs. We also co-develop therapeutics with pharmaceutical and biotech companies. CelerisTx has so far attracted a total of EUR 18 million in committed capital from venture capital funds, which include EIC Fund, Pace Ventures Enigma, i&i biotech, Apex Ventures, R42 and longevitytech.fund. #targetedproteindegradation #degrader #ubiquitinproteasomesystem #machinelearning #CelerisOne #proximityinducingcompounds #PICs
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Austria
1
Frequently asked questions
Who invested in Celeris Therapeutics?
Celeris Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Celeris Therapeutics last raise funding?
The most recent investment in Celeris Therapeutics recorded on gritt.io was in August 2021.
When was Celeris Therapeutics founded?
Celeris Therapeutics was founded in 2021.
What industry is Celeris Therapeutics in?
Celeris Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Celeris Therapeutics based?
Celeris Therapeutics is headquartered in Menlo Park, United States.